Literature DB >> 22807371

Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.

Li-Na Wang1, Shi-Wen Tong, Huai-Dong Hu, Feng Ye, Sang-Lin Li, Hong Ren, Da-Zhi Zhang, Rong Xiang, Yi-Xuan Yang.   

Abstract

Quantitative proteomics can be used as a screening tool for identification of differentially expressed proteins as potential biomarkers for cancers. Here, we comparatively analyzed the proteome profiles of ovarian cancer tissues and normal ovarian epithelial tissues. Using the high-throughput proteomic technology of isobaric tags for relative and absolute quantitation (iTRAQ)-coupled with two-dimensional-liquid chromatography-tandem mass spectrometry, 1,259 unique proteins were identified. Of those, 205 were potentially differentially expressed between ovarian cancer and normal ovarian tissues. Several of the potentially differentially expressed proteins were validated by Western blotting and real-time quantitative RT-PCR analyses. Furthermore, up-regulation of KRT8, PPA1, IDH2, and S100A11 were validated in ovarian tissue microarrays by immunohistochemistry. Silencing of S100A11 expression suppressed the migration and invasion properties of ovarian cancer cells in vitro. Our study represents the successful application of iTRAQ technology to an investigation of ovarian cancer. Many of the potentially differentially expressed proteins identified had not been linked to ovarian cancer before, and provide valuable novel insights into the underlying mechanisms of carcinogenesis in human ovarian cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22807371     DOI: 10.1002/jcb.24250

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.480


  15 in total

1.  A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.

Authors:  Gaofeng Fan; Kazimierz O Wrzeszczynski; Cexiong Fu; Gang Su; Darryl J Pappin; Robert Lucito; Nicholas K Tonks
Journal:  Biochem J       Date:  2015-02-01       Impact factor: 3.857

2.  Comparative proteomic analysis of renal tissue in IgA nephropathy with iTRAQ quantitative proteomics.

Authors:  Weiguo Sui; Zhenzhen Cui; Ruohan Zhang; Wen Xue; Minglin Ou; Guimian Zou; Jiejing Chen; Yong Dai
Journal:  Biomed Rep       Date:  2014-07-23

3.  Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.

Authors:  Isa N Cruz; Helen M Coley; Holger B Kramer; Thumuluru Kavitah Madhuri; Nur A M Safuwan; Ana Rita Angelino; Min Yang
Journal:  Cancer Genomics Proteomics       Date:  2017-01-02       Impact factor: 4.069

4.  Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.

Authors:  Na Li; Huanni Li; Ya Wang; Lanqin Cao; Xianquan Zhan
Journal:  EPMA J       Date:  2020-10-10       Impact factor: 6.543

5.  Knockdown of S100A11 expression suppresses ovarian cancer cell growth and invasion.

Authors:  Youqing Liu; Xiaobing Han; Baoan Gao
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

6.  Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer.

Authors:  Vivian Delcourt; Julien Franck; Eric Leblanc; Fabrice Narducci; Yves-Marie Robin; Jean-Pascal Gimeno; Jusal Quanico; Maxence Wisztorski; Firas Kobeissy; Jean-François Jacques; Xavier Roucou; Michel Salzet; Isabelle Fournier
Journal:  EBioMedicine       Date:  2017-06-03       Impact factor: 8.143

7.  Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.

Authors:  Hong Qu; Yuling Chen; Guangming Cao; Chongdong Liu; Jiatong Xu; Haiteng Deng; Zhenyu Zhang
Journal:  Oncotarget       Date:  2016-12-13

8.  MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.

Authors:  Xiang Zhou; Dimple Natino; Xu Zhai; Zhongyang Gao; Xijing He
Journal:  Mol Med Rep       Date:  2018-03-20       Impact factor: 2.952

9.  Clinical significance and functional validation of PPA1 in various tumors.

Authors:  Dehong Luo; Guanwen Wang; Wenzhi Shen; Shuangtao Zhao; Wei Zhou; Lin Wan; Liying Yuan; Shuang Yang; Rong Xiang
Journal:  Cancer Med       Date:  2016-09-26       Impact factor: 4.452

10.  Silencing PPA1 inhibits human epithelial ovarian cancer metastasis by suppressing the Wnt/β-catenin signaling pathway.

Authors:  Haiying Niu; Wei Zhou; Yingxi Xu; Zhiqi Yin; Wenzhi Shen; Zhen Ye; Yanhua Liu; Yanan Chen; Shuang Yang; Rong Xiang; Lina Wang; Pengpeng Qu
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.